Anterior Uveitis
Summary
Anterior uveitis (iritis/iridocyclitis) is inflammation of the iris and ciliary body, presenting as a painful red eye with photophobia, lacrimation, and blurred vision. It is the most common form of uveitis, accounting for 50-90% of cases. The condition is strongly associated with HLA-B27 and seronegative spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis, IBD-associated arthritis). While idiopathic in ~50% of cases, systemic diseases such as sarcoidosis, Behçet's, herpes infections, and tuberculosis must be considered. Treatment requires urgent ophthalmology referral, topical corticosteroids to reduce inflammation, and cycloplegic agents to relieve pain and prevent synechiae formation.
Key Facts
- Definition: Inflammation of the iris (iritis) ± ciliary body (iridocyclitis)
- Prevalence: Most common form of uveitis; 17-52 per 100,000
- Presentation: Painful red eye, photophobia, blurred vision, lacrimation
- Classic Sign: Ciliary flush (circumcorneal limbal injection)
- Slit Lamp: Cells and flare in anterior chamber
- Key Association: HLA-B27 (50% of anterior uveitis; 90% of AS-related uveitis)
- Key Management: Urgent ophthalmology; topical steroids + cycloplegics
Clinical Pearls
"Painful Red Eye with Photophobia = Think Uveitis": Unlike conjunctivitis (gritty, no photophobia, no visual loss) or episcleritis (localised, minimal pain), anterior uveitis causes deep aching pain, consensual photophobia, and vision changes.
Consensual Photophobia: Shining light in the UNAFFECTED eye causes pain in the AFFECTED eye. This is diagnostic of anterior uveitis — ciliary spasm is triggered bilaterally.
HLA-B27 Link: Up to 50% of anterior uveitis is HLA-B27 positive. Ask about back pain, stiffness, joint symptoms.
Why This Matters Clinically
Anterior uveitis requires prompt recognition and treatment to prevent complications such as posterior synechiae (iris adhesion to lens), glaucoma, cataract, and permanent visual loss. Recurrent episodes are common. Many cases indicate underlying systemic disease, making appropriate investigation important.
Incidence & Prevalence
- Incidence: 17-52 per 100,000 per year
- Prevalence: 38-114 per 100,000
- Proportion of uveitis: 50-90% of all uveitis cases
- Trend: Stable; increasing recognition
Demographics
| Factor | Details |
|---|---|
| Age | Peak 20-50 years; can occur at any age |
| Sex | Slight male predominance in HLA-B27 positive cases; otherwise equal |
| Ethnicity | Parallels HLA-B27 prevalence; higher in Caucasians, Native Americans |
| Geography | Higher in northern Europe (HLA-B27 frequency) |
Risk Factors
| Factor | Details |
|---|---|
| HLA-B27 | Present in ~50% of anterior uveitis; stronger predictor of recurrence |
| Seronegative spondyloarthropathy | Ankylosing spondylitis (AS), psoriatic arthritis, reactive arthritis, IBD-associated |
| Previous episode | Recurrence common (40-50%) |
| Systemic inflammatory disease | Sarcoidosis, Behçet's disease |
| Infection | Herpes simplex/zoster, tuberculosis, syphilis, Lyme disease |
| Smoking | May increase risk of recurrence |
Aetiology Classification
| Category | Examples | Frequency |
|---|---|---|
| Idiopathic | No identifiable cause | ~50% |
| HLA-B27 associated | AS, reactive arthritis, psoriatic arthritis, IBD-arthritis | 20-30% |
| Infectious | Herpes simplex, herpes zoster, TB, syphilis, Lyme, toxoplasmosis | 5-10% |
| Systemic inflammatory | Sarcoidosis, Behçet's, JIA, TINU syndrome | 5-15% |
| Masquerade syndromes | Lymphoma, leukaemia, retinoblastoma (pseudo-uveitis) | Rare |
Mechanism
Step 1: Immune Activation
- Breakdown of ocular immune privilege
- T-cell mediated inflammation (usually CD4+ Th1 or Th17)
- Antigen presentation by iris/ciliary body macrophages
- Cytokine release (IL-1, IL-6, TNF-alpha, IFN-gamma)
Step 2: Blood-Aqueous Barrier Breakdown
- Increased vascular permeability
- Protein leakage into anterior chamber (flare)
- Inflammatory cell infiltration (cells)
- Fibrin deposition (if severe)
Step 3: Clinical Manifestations
- Ciliary muscle spasm → photophobia, pain
- Inflammatory cells/protein in anterior chamber → vision blur
- Pupil constriction (miosis)
- Iris vascular engorgement
Step 4: Complications
- Posterior synechiae (iris adhesion to lens) → irregular pupil
- Seclusio pupillae (360° synechiae) → pupil block glaucoma
- Trabecular meshwork obstruction → secondary open-angle glaucoma
- Chronic inflammation → cataract
- Band keratopathy (calcium deposition in cornea)
HLA-B27 Mechanism
- Molecular mimicry with bacterial antigens
- Arthritogenic peptide presentation
- Microbiome dysbiosis
- Cross-reactive T-cell response between gut/joint/eye
Symptoms
Classic Triad:
Additional Symptoms:
Signs
| Sign | Description |
|---|---|
| Ciliary flush (limbal injection) | Circumcorneal ring of redness around the cornea; deeper than conjunctivitis |
| Cells in anterior chamber | WBCs seen floating in aqueous on slit lamp (graded 0-4+) |
| Flare | Protein in aqueous causing "beam" visible on slit lamp (Tyndall effect) |
| Miosis | Small pupil (due to sphincter spasm) |
| Posterior synechiae | Iris adhesion to lens; irregular pupil |
| Hypopyon | White layering of pus in lower anterior chamber (severe inflammation) |
| Keratic precipitates (KPs) | Inflammatory deposits on posterior cornea |
Red Flags
[!CAUTION] Red Flags — Urgent investigation/management required:
- Hypopyon — Consider endophthalmitis (infectious), Behçet's, HLA-B27 severe flare
- Significant visual loss — Posterior segment involvement, macular oedema
- Elevated IOP — Secondary glaucoma
- Bilateral simultaneous onset — Strongly suggests systemic disease
- Chronic/recurrent despite treatment — Investigate for underlying cause
- Posterior segment signs — Vitritis, chorioretinitis (not just anterior)
Structured Approach
General Inspection:
- Red eye with circumcorneal (limbal) injection
- Photophobia on examination
- May be tearing
Visual Acuity:
- Document before and after dilation
- May be reduced (usually mild unless complications)
Pupil Examination:
- Miosis (small, reactive)
- Irregular if posterior synechiae present
- Test consensual photophobia (light in unaffected eye → pain in affected eye)
Slit Lamp Examination (Key):
| Finding | Grade | Significance |
|---|---|---|
| Cells (WBCs in AC) | 0 to 4+ | Activity marker |
| Flare (protein in AC) | 0 to 4+ | BAB breakdown; chronicity |
| Keratic precipitates | Fine/granulomatous | Fine = non-granulomatous; "mutton-fat" = granulomatous (sarcoid, TB) |
| Hypopyon | Present/absent | Severe inflammation |
| Posterior synechiae | Present/absent | Complication; dilate to break |
| Iris nodules | Koeppe/Busacca | Granulomatous; consider sarcoid |
Intraocular Pressure (IOP):
- May be low (ciliary shutdown) or high (trabecular obstruction)
Fundoscopy:
- Rule out posterior segment involvement
- Vitritis suggests intermediate/posterior uveitis
Special Tests
| Test | Purpose |
|---|---|
| Slit lamp biomicroscopy | Essential; diagnose and grade inflammation |
| Tonometry | Measure IOP |
| Dilated fundoscopy | Rule out posterior involvement |
| Gonioscopy | If angle closure concern |
First-Line (First Episode, Uncomplicated)
May not require extensive workup if:
- First episode
- Unilateral
- Resolves quickly with treatment
- No systemic symptoms
Investigate if Recurrent, Bilateral, or Atypical
| Test | Purpose |
|---|---|
| HLA-B27 | Strong association; guides follow-up |
| Chest X-ray | Sarcoidosis, tuberculosis |
| ACE level | Sarcoidosis |
| Syphilis serology (VDRL/TPHA) | Exclude syphilis |
| FBC, CRP/ESR | Inflammatory markers |
| Quantiferon/Mantoux | Tuberculosis |
| Urinalysis | Tubulointerstitial nephritis (TINU syndrome) |
Specialist Investigation
| Investigation | Indication |
|---|---|
| OCT macula | Cystoid macular oedema |
| Fluorescein angiography | Posterior segment, vasculitis |
| B-scan ultrasound | If poor view of fundus |
| Lumbar puncture | CNS involvement suspected (MS, Behçet's) |
Management Algorithm
Immediate Management
| Action | Details |
|---|---|
| Urgent ophthalmology referral | Same-day/next-day specialist review essential |
| Topical corticosteroids | Prednisolone acetate 1% hourly initially, then taper |
| Cycloplegic agents | Cyclopentolate 1% TDS or Atropine 1% BD — relieves pain, prevents synechiae |
Pharmacological Management
| Drug | Class | Dose | Purpose |
|---|---|---|---|
| Prednisolone 1% | Topical steroid | Hourly initially → taper over weeks | Reduce inflammation |
| Dexamethasone 0.1% | Topical steroid | Alternative to prednisolone | Stronger penetration |
| Cyclopentolate 1% | Cycloplegic | TDS | Short-acting; pain relief |
| Atropine 1% | Cycloplegic | BD | Long-acting; prevent synechiae |
| Homatropine 2% | Cycloplegic | TDS | Intermediate duration |
Follow-Up and Monitoring
- Review in 1-7 days depending on severity
- Continue steroids until cells clear, then slow taper (risk of rebound)
- Monitor IOP (steroid response)
- Taper cycloplegics once inflammation controlled
Management of Complications
| Complication | Management |
|---|---|
| Posterior synechiae | Intensive mydriatics to break synechiae; subconjunctival mydriatics if resistant |
| Secondary glaucoma | IOP-lowering drops (avoid prostaglandins in active inflammation) |
| Cataract | Surgery when inflammation controlled |
| CMO | Intensive topical steroids, peri-ocular/systemic steroids |
Systemic Treatment (Recurrent/Severe)
| Indication | Options |
|---|---|
| Refractory to topical | Periocular steroid injection |
| Frequent recurrence | Systemic methotrexate, mycophenolate, azathioprine |
| Behçet's, severe HLA-B27 | Adalimumab (anti-TNF), infliximab |
| Underlying disease | Treat AS, sarcoidosis, etc. |
Complications of Anterior Uveitis
| Complication | Mechanism | Management |
|---|---|---|
| Posterior synechiae | Iris adherence to lens | Mydriatics; may need surgical lysis |
| Seclusio pupillae | 360° synechiae; iris bombe | Laser iridotomy |
| Secondary glaucoma | Trabecular obstruction, pupil block | IOP-lowering treatment |
| Cataract | Chronic inflammation or steroids | Surgery when quiet |
| Band keratopathy | Calcium deposition (chronic) | EDTA chelation |
| Cystoid macular oedema | Chronic BAB breakdown | Steroids; anti-VEGF |
| Phthisis bulbi | End-stage; ciliary shutdown | Rare; enucleation if painful |
Treatment-Related Complications
| Treatment | Complication |
|---|---|
| Topical steroids | Steroid-induced glaucoma, cataract (prolonged use), rebound inflammation (too rapid taper) |
| Cycloplegics | Blurred vision, photophobia, accommodation loss |
Natural History
Acute anterior uveitis typically resolves within weeks with appropriate treatment. However, recurrence is common (40-50%), particularly in HLA-B27 positive patients. Chronic or recurrent cases may develop complications leading to permanent visual impairment.
Outcomes
| Outcome | Rate |
|---|---|
| Resolution with treatment | 95%+ for acute episode |
| Recurrence | 40-50% overall; higher in HLA-B27+ |
| Vision loss | 5-10% with complications |
| Chronic uveitis | 10-15% develop chronic course |
Prognostic Factors
Good Prognosis:
- First episode
- Acute presentation
- Good response to topical steroids
- No synechiae
- No underlying chronic disease
Poor Prognosis:
- Recurrent episodes
- HLA-B27 positive (more recurrences)
- Granulomatous uveitis
- Posterior involvement
- Systemic disease (Behçet's, JIA)
- Complications present at diagnosis
Key Guidelines
- NICE CKS: Red Eye (2023) — Primary care guidance on referral and initial management.
- American Academy of Ophthalmology Uveitis Preferred Practice Pattern (2019) — Comprehensive specialist guidance.
- British Society for Rheumatology HLA-B27 SpA Guidelines — Management of associated spondyloarthropathy.
Key Studies
Adalimumab for Uveitis (VISUAL 1 & 2 Trials, 2016) — Adalimumab effective for non-infectious intermediate, posterior, and panuveitis.
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| Topical steroids for acute AU | Expert consensus | Standard of care; no RCTs vs placebo |
| Cycloplegics | Expert consensus | Reduces pain, prevents synechiae |
| Adalimumab for recurrent/refractory | 1b | VISUAL trials |
| HLA-B27 testing in recurrent AU | Expert consensus | Guides systemic evaluation |
What is Anterior Uveitis?
Anterior uveitis is inflammation inside the front part of the eye, affecting the iris (the coloured part) and the ciliary body (which focuses the lens). It causes a painful, red eye with sensitivity to light and blurred vision. It is sometimes called "iritis."
Why does it happen?
- In about half of cases, no specific cause is found
- It's often linked to a gene called HLA-B27, which is also associated with types of arthritis affecting the spine
- Infections (herpes, tuberculosis) and other inflammatory conditions (sarcoidosis, Behçet's) can cause it
- It can keep coming back, especially if you have HLA-B27
How is it treated?
- Eye drops: Steroid drops to reduce inflammation (used frequently at first, then tapered slowly)
- Dilating drops: To relieve pain and prevent the iris from sticking to the lens
- Follow-up: Regular eye checks until inflammation clears and drops are stopped
- Investigation: If it keeps coming back, blood tests and X-rays may be needed to look for underlying causes
What to expect
- Most episodes clear up within a few weeks with treatment
- It can come back — 40-50% of people have another episode
- If you have HLA-B27 or a related condition, recurrences are more likely
- Stopping drops too quickly can cause the inflammation to return
When to seek help
- If you have a painful red eye with sensitivity to light — see a doctor the same day
- If your vision gets worse
- If you see a white layer at the bottom of your eye (hypopyon)
- If you have back pain or joint stiffness (may indicate underlying arthritis)
Primary Guidelines
- National Institute for Health and Care Excellence. Red eye. NICE Clinical Knowledge Summaries. 2023. NICE CKS
- Jabs DA, et al. Standardization of uveitis nomenclature (SUN). Am J Ophthalmol. 2005;140(3):509-516. PMID: 16196117
Key Trials
- Jaffe GJ, et al. Adalimumab in patients with active noninfectious uveitis (VISUAL I). N Engl J Med. 2016;375(10):932-943. PMID: 27602665
- Nguyen QD, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis (VISUAL II). Lancet. 2016;388(10050):1183-1192. PMID: 27457817
- Rothova A, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332-336. PMID: 8703883
Further Resources
- Fight for Sight: www.fightforsight.org.uk
- Moorfields Eye Hospital: www.moorfields.nhs.uk
- Uveitis Information Group: www.uveitis.net
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Anterior uveitis requires urgent specialist assessment — seek same-day ophthalmology review if suspected. This content does not constitute medical advice for individual patients.